drugset / Trial / NCT06766565

QYJD Compound Preparation Promotes Rapid Postoperative Recovery in Early-stage NSCLC Patients by Regulating Tissue Microecology: a Prospective, Randomized Controlled, Open-label, Phase I Clinical Study With Predefined Future Exploration

NCT06766565 ↗

Phase 1 Completed 15 enrolled Fuzhou General Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

QYJD compound preparation has the efficacy of clearing heat and removing toxins, dispelling blood stasis and relieving pain, etc. investigators aimed to explore the effect of expelling blood stasis and removing toxins compound preparation on the microecological changes of lungs of patients with early stage non-small cell lung cancer (NSCLC) by using metagenomics next-generation sequencing (mNGS) technology to carry out a prospective phase I clinical study. The aim of the study was to investigate the effect of the expelling stasis and detoxifying compound preparation on the microecology of lungs of patients with early-stage non-small cell lung cancer (NSCLC), and to conduct a prospective phase I clinical study to provide new ideas for promoting the postoperative rehabilitation of early-stage NSCLC.

Timeline

Start
2021-12-08
Primary completion
2022-12-08
Completion
2023-12-08

Drugs

EvaluationDrugModalityDoseRoute
Subject QYJD Compound Preparation Unknown 0.6 g Oral